The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

@article{Rylova2018TheSR,
  title={The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model},
  author={S. Rylova and C. Stoykow and Luigi Del Pozzo and Keelara Abiraj and M. L. Tamma and Y. Kiefer and M. Fani and H. M{\"a}cke},
  journal={PLoS ONE},
  year={2018},
  volume={13}
}
  • S. Rylova, C. Stoykow, +5 authors H. Mäcke
  • Published 2018
  • Chemistry, Medicine
  • PLoS ONE
  • Copper-64 is an attractive radionuclide for PET imaging and is frequently used in clinical applications. The aim of this study was to perform a side-by-side comparison of the in vitro and in vivo performance of 64Cu-NODAGA-JR11 (NODAGA = 1,4,7-triazacyclononane,1-glutaric acid,4,7-acetic acid, JR11 = p-Cl-Phe-cyclo(D-Cys-Aph(Hor)-D-Aph(cbm)-Lys-Thr-Cys)D-Tyr-NH2), a somatostatin receptor 2 antagonist, with the clinically used sst2 agonist 64Cu-DOTA-TATE ((TATE = D-Phe-cyclo(Cys-Tyr-D-Trp-Lys… CONTINUE READING
    11 Citations
    Design and development of the theranostic pair 177 Lu-OPS201/68 Ga-OPS202 for targeting somatostatin receptor expressing tumors.
    • R. Mansi, M. Fani
    • Chemistry, Medicine
    • Journal of labelled compounds & radiopharmaceuticals
    • 2019
    • 5
    Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
    • 12
    • PDF

    References

    SHOWING 1-10 OF 34 REFERENCES
    Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    • 344
    • PDF
    Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
    • 73
    • PDF
    First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
    • 127
    • PDF
    Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    • 38